Navigation Links
AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results
Date:5/6/2009

All amounts are in U.S. dollars

QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three months ended March 31, 2009.

    First Quarter 2009 Highlight

    Signing of partnership with sanofi-aventis for cetrorelix in benign
prostatic hyperplasia ("BPH") for the U.S. market:

    - Initial $30 million upfront payment to the Company;
    - Up to $135 million in additional payments upon achieving certain
      pre-established regulatory and commercial milestones;
    - Escalating double-digit royalties on future net sales of cetrorelix for
      BPH in the U.S.;
    - Sanofi-aventis responsible for the commercialization and booking of
      sales in the U.S.;
    - The Company retained certain rights to co-promote cetrorelix for BPH in
      the U.S.

Juergen Engel, Ph.D., AEterna Zentaris' President and Chief Executive Officer commented, "The first quarter of 2009 was marked by the signing of a major agreement with sanofi-aventis for the development, registration and marketing of our lead compound, cetrorelix, in BPH for the United States market. The agreement is an important milestone in our quest to bring cetrorelix to market, provide millions of men with a novel treatment for BPH and generate significant long-term revenue for the Company. We expect to disclose results of our Phase 3 program with cetrorelix in BPH over the next few months as we continue to evaluate other strategic partnerships for this compound. Furthermore, we will push forward our promising drug candidates in oncology, such as AEZS-108 and AEZS-112, while in collaboration with our partners, we expect to move perifosine and ozarelix to
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007
2. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Little Rock, AR (PRWEB) August 20, 2014 ... for providers to require a medical exam before issuing ... reports. The Quotes Pros company is now helping the ... medical exam through its system at http://quotespros.com/life-insurance.html . ... past two decades as more regulations have appeared in ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... a group of rhesus monkeys from deadly Marburg virus, a ... 90 percent of those it infects, researchers report. The ... virus, even when it was given three days after infection, ... Science Translational Medicine . This is the first ...
(Date:8/20/2014)... deploy Ebola vaccines is now, Free content, The ... to a commentary being published early online today in ... authors from Yale School of Public Health write that ... current Ebola outbreak represent a public health crisis that ... Ebola vaccines have been developed in the last decade, ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... a condition that causes a life-threatening irregular heartbeat, a new ... percent lower risk of developing atrial fibrillation, compared to women ... issue of the Journal of the American Heart Association ... rhythm disorder even if they were obese, the study found. ...
(Date:8/20/2014)... one of the most persistent and deadliest infectious diseases ... each year. , Scientists who study tuberculosis have long ... spread from humans in Africa to seals and sea ... transmitted it to Native people there before Europeans landed ... Reveal Seals as a Source of New World Human ...
Breaking Medicine News(10 mins):Health News:Life Insurance Quotes Without Medical Exams Now Displayed to Adults at Insurance Website 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:News from Annals of Internal Medicine 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3
... A Pneumonia Report Card released today by the International ... Coalition against Child Pneumonia reveals where urgent efforts are ... life-saving interventions that can prevent, protect against and treat ... leading infectious killer of young children, taking the lives ...
... The November 2010 issue of the Archives of ... American Congress of Rehabilitation Medicine, has published a set ... will accelerate future research in the field by establishing ... is measured and classified, treatment and potential outcomes. It ...
... This release is available in French . ... and depression should receive an additional cardiac test when undergoing ... from Concordia University, the Universit du Qubec Montral and ... study, published in the Journal of Cardiopulmonary Rehabilitation and ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, Nov. ... prescription drug plans will come across some changes as they ... the upcoming open enrollment period, but experts say those differences ... continues through Dec. 31, and any changes will take effect ...
... intensive calculations in the supercomputer MareNostrum at the Barcelona ... Institute for Research in Biomedicine (IRB Barcelona) have presented ... MoDEL, this new database holds more than 1,700 proteins ... MoDEL has been developed to study the basic biology ...
... the body than just damaging the liver. Drinking also can ... the risk of HIV transmission and hinder recovery from burns, ... on such negative effects of alcohol during a meeting Nov. ... at Loyola University Medical Center. , At Loyola, about 50 ...
Cached Medicine News:Health News:Efforts to combat pneumonia among 15 high-burdened countries fall short of recommended targets 2Health News:Efforts to combat pneumonia among 15 high-burdened countries fall short of recommended targets 3Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 2Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 3Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 4Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 5Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 6Health News:Additional cardiac testing vital for patients with anxiety and depression 2Health News:Medicare Part D Changes Not Overwhelming, Experts Say 2Health News:Medicare Part D Changes Not Overwhelming, Experts Say 3Health News:Scientists at IRB Barcelona and BSC publish the world's largest video data bank of proteins 2
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. announces ... Ltd., has received Chinese FDA (CFDA) approval and ... Tablets into the China ... and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., ... US FDA approved and China CFDA certified oral ...
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... -- Trovagene, Inc. (NASDAQ:   TROV), a developer of ... clinical studies will be presented at the 29th International ... for the detection of high risk strains of Human ... place in Seattle from August ... new U.S. patent was issued earlier this year for ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... , , , ... Exposure of Type I Diabetes Patients to Oramed,s Oral,Insulin and of a First-in-Humans Study With ... Oramed Pharmaceuticals, ... of the,American Diabetes Association currently being held in Orlando, Florida . Dr., Miriam Kidron ...
... WASHINGTON , June 28 Harris Corporation (NYSE: ... Inc., is helping to improve the quality of military patient ... Information Exchange (BHIE) interface.  The exchange is a health enterprise ... the Department of Veterans Affairs (VA) to securely share patient ...
Cached Medicine Technology:Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association 2Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association 3Harris Corporation Leverages CONNECT Solution to Enhance Patient Information Exchange Between DoD and VA 2
... electrophoresis system is designed to automate ... classic electrophoresis and immunofixation testing. The ... of electrophoresis from sample application ... destaining and drying. The walkaway nature ...
... FRECHET EXTENDER® is a new device for ... its silicone elastomer strips, it allows a ... tissues, well beyond other devices capacities. Such ... term implant since it is removed before ...
Inquire...
Inquire...
Medicine Products: